RV
RVTY.US Revvity Inc.
- Market cap
- USD 16.5B
- P/E
- 66.3x
- P/B
- 2.29x
- ROE
- 2.8%
- Dividend yield
- 0.20%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RVTY.US undervalued?
Graham numberRVTY.US trades 159.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Revvity Inc. fundamental analysis
No fundamental analysis for Revvity Inc. yet.
Revvity Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Revvity Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for …
Full company profileRevvity Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Revvity Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.12B | 2.26B | 2.78B | 2.88B | 3.78B | 3.83B | 3.31B | 2.75B | 2.76B | 2.86B | 2.89B |
| Gross Profit | 972M | 1.03B | 1.25B | 1.29B | 1.99B | 2.28B | 1.76B | 1.32B | 1.32B | 1.52B | 1.63B |
| Operating Income | 306M | 305M | 371M | 405M | 1.02B | 1.34B | 781M | 399M | 411M | 357M | 347M |
| EBITDA | 386M | 446M | 505M | 515M | 1.16B | 1.62B | 1.18B | 714M | 840M | 766M | 760M |
| Net Income | 234M | 113M | 239M | 228M | 728M | 943M | 569M | -118M | 296M | 242M | 206M |
| EPS | 2.12 | 1.02 | 2.14 | 2.04 | 6.50 | 8.08 | 4.50 | -0.95 | 2.41 | 2.13 | 1.85 |
| Balance Sheet | |||||||||||
| Total Assets | 4.28B | 6.09B | 5.98B | 6.54B | 7.96B | 15.0B | 14.1B | 13.6B | 12.4B | 12.2B | 11.5B |
| Total Liabilities | 2.12B | 3.59B | 3.39B | 3.72B | 4.22B | 7.86B | 6.75B | 5.69B | 4.73B | 4.92B | 4.22B |
| Shareholders' Equity | 2.15B | 2.50B | 2.58B | 2.81B | 3.74B | 7.14B | 7.38B | 7.87B | 7.67B | 7.25B | 7.27B |
| Cash & Short-term Investments | 359M | 202M | 163M | 192M | 402M | 603M | 454M | 1.60B | 1.16B | 920M | 593M |
| Total Debt | 1.05B | 2.01B | 1.89B | 2.26B | 2.22B | 5.16B | 4.60B | 4.07B | 3.33B | 3.52B | 2.77B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 351M | 288M | 311M | 363M | 892M | 1.41B | 680M | 91.3M | 628M | 582M | 632M |
| Capital Expenditure | 31.7M | 39.1M | 93.3M | 81.3M | 77.5M | 99.9M | 85.6M | 81.4M | 86.6M | 73.5M | 60.3M |
| Free Cash Flow | 319M | 249M | 218M | 282M | 815M | 1.31B | 594M | 9.90M | 542M | 508M | 572M |
| Ratios | |||||||||||
| ROE | 10.9% | 4.5% | 9.2% | 8.1% | 19.5% | 13.2% | 7.7% | -1.5% | 3.9% | 3.3% | 2.8% |
| ROA | 5.5% | 1.9% | 4.0% | 3.5% | 9.1% | 6.3% | 4.0% | -0.9% | 2.4% | 2.0% | 1.8% |
| Net Profit Margin | 11.0% | 5.0% | 8.6% | 7.9% | 19.2% | 24.6% | 17.2% | -4.3% | 10.7% | 8.5% | 7.1% |
| Debt to Equity | 0.49x | 0.80x | 0.73x | 0.80x | 0.59x | 0.72x | 0.62x | 0.52x | 0.43x | 0.48x | 0.38x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Revvity Inc. dividends
- Dividend yield
- 0.20%
- Forward dividend
- 0.28 USD
- Payout ratio
- 13.6%
- Ex-dividend date
- Jan 22, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 32.8M | 0.29 | 13.6% |
| 2024 | USD 34.5M | 0.28 | 11.6% |
| 2023 | USD 35.0M | 0.28 | - |
| 2022 | USD 35.3M | 0.28 | 6.2% |
| 2021 | USD 32.4M | 0.28 | 3.4% |
| 2020 | USD 31.2M | 0.28 | 4.3% |
| 2019 | USD 31.1M | 0.28 | 13.6% |
| 2018 | USD 31.0M | 0.28 | 13.0% |
| 2017 | USD 30.8M | 0.28 | 27.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 4, 2001.
Who owns Revvity Inc.
- Insiders 0.26%
- Institutions 99.74%
- Public & others 0.00%
- Shares outstanding 112M
- Free float 103M
Top funds holding RVTY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Janus Henderson Enterprise D | 4.83M | 4.33% | -16.01% | Sep 2026 |
| T. Rowe Price Capital Appreciation | 4.78M | 4.28% | -16.16% | Sep 2026 |
| EdgePoint Global Portfolio Series F | 3.60M | 3.23% | -2.15% | Jun 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.55M | 3.18% | +0.27% | Sep 2026 |
| Vanguard 500 Index Investor | 2.93M | 2.62% | -1.15% | Sep 2026 |
| Vanguard Small Cap Index | 2.51M | 2.25% | -2.16% | Sep 2026 |
| T. Rowe Price Value | 2.00M | 1.79% | 0.00% | Sep 2026 |
| Victory Sycamore Established Value R | 1.84M | 1.64% | -24.02% | Sep 2026 |
| EdgePoint Global Growth & Inc Port Sr F | 1.72M | 1.54% | -3.54% | Jun 2026 |
| Vanguard MStar Small Cap Value Index | 1.63M | 1.46% | +0.29% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 1.59M | 1.43% | +0.17% | Oct 2026 |
| iShares Core S&P 500 ETF | 1.49M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.45M | 1.30% | +0.14% | Sep 2026 |
| Allspring Special Mid Cap Value Inst | 1.39M | 1.25% | -15.04% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 1.36M | 1.22% | -0.25% | Oct 2026 |
| Pictet-Security I USD | 1.31M | 1.18% | +0.58% | Jul 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 1.10M | 0.99% | -55.86% | Sep 2026 |
| T. Rowe Price US Large-Cap Core | 982K | 0.88% | +18.79% | Sep 2026 |
| Neuberger Genesis Inv | 856K | 0.77% | -12.08% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 816K | 0.73% | +0.88% | Oct 2026 |
Top institutions holding RVTY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 18.3M | 16.36% | -17.74% | Jun 2026 |
| Jupiter Topco LLC | 8.64M | 7.74% | 0.00% | Jun 2026 |
| EdgePoint Investment | 8.54M | 7.65% | -2.91% | Jun 2026 |
| BlackRock Inc | 7.66M | 6.86% | +5.63% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.30M | 6.54% | -0.40% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 5.53M | 4.96% | -45.19% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.77M | 4.27% | -0.89% | Jun 2026 |
| State Street Corp | 4.34M | 3.89% | +0.75% | Jun 2026 |
| Victory Capital Management Inc. | 3.65M | 3.27% | +8.10% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.41M | 3.06% | -0.44% | Sep 2026 |
| Geode Capital Management, LLC | 2.96M | 2.65% | +0.62% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.57M | 2.31% | -4.03% | Jun 2026 |
| Amvescap Plc. | 2.42M | 2.17% | -10.78% | Jun 2026 |
| Allspring Global Investments Holdings, LLC | 2.23M | 2.00% | -1.39% | Jun 2026 |
| Neuberger Berman Group LLC | 1.88M | 1.68% | +35.22% | Jun 2026 |
| UBS Group AG | 1.86M | 1.67% | +37.54% | Jun 2026 |
| Pictet Asset Manangement SA | 1.63M | 1.46% | +81.80% | Jun 2026 |
| Citadel Advisors Llc | 1.46M | 1.31% | +2,226.04% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.09M | 0.97% | +0.02% | Jun 2026 |
| Vaughan Nelson Scarbrgh & Mccullough LP | 1.08M | 0.97% | +134.19% | Jun 2026 |
Revvity Inc. company profile
- Company name
- Revvity Inc.
- Ticker
- RVTY.US
- Exchange
- USA Stocks
- Listed since
- Apr 6, 1983
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 11,000
- Fiscal year end
- December
- Address
- 77 4th Avenue, Waltham, MA, United States, 02451
- Phone
- 781 663 6900
- Website
- revvity.com
About Revvity Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Revvity Inc. management
10- Dr. Prahlad R. Singh Ph.D.CEO, President & Director · born 1965
- Mr. Maxwell KrakowiakSenior VP & CFO · born 1990
- Mr. Tajinder S. VohraSenior Vice President of Global Operations · born 1966
- Mr. Joel S. GoldbergSenior VP of Administration, General Counsel & Secretary · born 1969
- Ms. Miriame VictorSenior Vice President & Chief Business Officer · born 1981
- Ms. Anita GonzalesChief Accounting Officer, VP & Controller · born 1976
- Mr. Bryan A. KippSenior VP of Technology & Licensing
- Dr. Madhuri Hegde FACMG, Ph.D.Senior VP & Chief Scientific Officer
- Mr. Stephen Barr WilloughbySenior VP of Investor Relations & Head of ESG
- Ms. Magali FourSenior VP and Chief People & Culture Officer